STOCK TITAN

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

IMV Inc. (NASDAQ: IMV; TSX: IMV) announced a conference call on March 16, 2023, at 8:00 a.m. ET to discuss its 2022 fourth quarter and fiscal year-end financial results. The company is focused on developing immune-educating therapies for various cancers using its DPX platform, particularly the lead candidate MVP-S, which targets the survivin cancer antigen. MVP-S is undergoing clinical evaluation for multiple cancer types, including Diffuse Large B Cell Lymphoma and ovarian cancer. Investors and analysts can register for the call online or access a recorded version via IMV's website, available for 30 days post-event.

Positive
  • IMV's lead candidate MVP-S has demonstrated clinical benefits in multiple cancer indications.
  • MVP-S treatment has shown good tolerability and a robust anti-tumor immune response.
  • The company is advancing its clinical trials, indicating strong development momentum.
Negative
  • None.

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.

Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information.

Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

About IMV

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

IMV Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In this press release, such forward-looking statements include, but are not limited to, statements regarding the potential and efficacy of MVP-S, the potential impact of the VITALIZE study and timing of availability of the ORR from the remaining stage one patients from its Phase 2B trial, the Company’s ability to advance its development strategy, and the prospects for its lead immunotherapy and its other pipeline of immunotherapy candidates. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the detailed results when presented being at least consistent with the initial results from the VITALIZE Phase 2B trial, the Company’s priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

Investor Relations & Media

Delphine Davan

Senior Director, Communications and Investor Relations

IMV Inc.

O: (902) 492.1819 ext: 1049

E: ddavan@imv-inc.com

Source: IMV Inc.

FAQ

What are the key details of IMV's conference call on March 16, 2023?

IMV's conference call will be held on March 16, 2023, at 8:00 a.m. ET to discuss the 2022 fourth quarter and fiscal year-end financial results.

What is the focus of IMV's lead candidate MVP-S?

MVP-S is focused on delivering an immune response against the survivin cancer antigen, targeting its use in various cancers.

How is IMV performing in its clinical trials?

IMV has reported clinical benefits from MVP-S in multiple cancer types, highlighting its ongoing trials for cancers like DLBCL and ovarian cancer.

IMV

NASDAQ:IMV

IMV Rankings

IMV Latest News

IMV Stock Data

9.81M
10.17M
0.41%
20.37%
2.66%
Biotechnology
Healthcare
Link
Canada
Dartmouth